The PROPEL™ mometasone furoate family of implants

The PROPEL family of implants release mometasone furoate and have been shown to reduce inflammation and scarring leading to a reduction in the need for postoperative surgical and/or oral steroid interventions.^1-3

PROPEL™ clinical data

Reimbursement resources

PROPEL™ case videos

90-day outcomes of frontal sinus placement compared to surgery alone in AERD/Samter's Triad patient.

Individual results may vary.

PROPEL Contour mometasone furoate sinus implant frontal sinus placement vs. balloon dilation alone in a primary ESS patient.

Individual results may vary.

Multiple implant placement after primary sinus surgery.

Individual results may vary.

The PROPEL sinus implants are intended to maintain patency and locally deliver steroid to the sinus mucosa in patients ≥18 years of age following sinus surgery: PROPEL for the ethmoid sinus, PROPEL Mini for the ethmoid sinus/frontal sinus opening, and PROPEL Contour for the frontal/maxillary sinus ostia. Contraindications include patients with confirmed hypersensitivity or intolerance to mometasone furoate (MF) or hypersensitivity to bioabsorbable polymers. Safety and effectiveness of the implant in pregnant or nursing females have not been studied. Risks may include, but are not limited to, pain/ pressure, displacement of the implant, possible side effects of intranasal MF, sinusitis, epistaxis, and infection.
See full prescribing information (IFU).
Rx only.

Connect with us

First Name*

Last Name*

Company

Email*

Profession

Role

Primary Specialty

Country/Region*

City*

State*

Zip Code

Would you like to receive emails from Medtronic?*

I have read and agree with the Terms and Conditions*

Your information will be used and protected in accordance with our privacy statement.

Instructions For Use

PROPEL™: US | EU | Patient Implant Information Leaflet (EU)
PROPEL™ Mini: US | EU | Patient Implant Information Leaflet (EU)
PROPEL™ Mini with SDS: US
PROPEL™ Contour: US | EU